Literature DB >> 16523306

Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?

Focke Ziemssen1, Rayime Wegner, Jürgen Wegner, Olcay Tatar, Daniela Süsskind, Faik Gelisken, Martin Rohrbach, Karl U Bartz-Schmidt, Salvatore Grisanti.   

Abstract

BACKGROUND: Endoglin/CD105 is a transmembrane regulatory receptor for transforming growth factor-beta (TGF-beta) that is predominantly expressed on proliferating endothelial cells (ECs) in culture and on angiogenic blood vessels in vivo. Endoglin has been associated with angiogenesis and prognosis in several malignancies. Although microvascular structure has been characterized by a variety of different other endothelial markers so far, there is no consensus on the prognostic value of microvessel quantification in uveal melanoma due to differences in tissue pretreatment, variability in the reactivity of endothelial cell markers, blood vessel counting methods, and vasculogenic mimicry by melanoma cells expressing endothelial cell markers. The aim of this study was to investigate the expression pattern of endoglin and to evaluate whether proliferative activity of ECs determines the clinical prognosis of uveal melanoma.
METHODS: Paraffin sections from 35 clinicopathologically well-characterized cases of primary uveal melanomas were stained for Ki-67, von Willebrand factor (vWF) and endoglin. In 16 cases, metastatic disease led to death. The mean follow-up of the nonmetastasized cases was 10.6 (9-13) years. The immunohistological specimens were evaluated by three independent observers who were masked to the follow-up of patients. Statistical analyzes included Kaplan-Meier survival curves and the fitting of log-rank and Wilcoxon test models.
RESULTS: Immunohistochemistry with vWF confirmed that all examined specimens were vascularized. Expression of Ki-67 could be found in 26 (74%) of the samples. Moderate to high expression of endoglin was found in 13 cases (37%). Kaplan-Meier analysis showed a significant association (p<0.001) between an enhanced endoglin expression and death due to metastatic uveal melanoma.
CONCLUSIONS: The study demonstrates for the first time that the expression of endoglin can be used as a specific marker for angiogenesis in uveal melanomas. Thus, differentiation between the quiescent and proliferating ECs enables the location and characterization of hot spots of angiogenesis in melanomas. The data suggest not only a prognostic relevance in individual patients but promise applications in assessing the efficacy of antiangiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16523306     DOI: 10.1007/s00417-005-0135-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

Review 1.  Vasculogenic mimicry: how convincing, how novel, and how significant?

Authors:  D M McDonald; L Munn; R K Jain
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party.

Authors: 
Journal:  Lancet       Date:  2000-05-20       Impact factor: 79.321

Review 3.  CD 105 and angiogenesis.

Authors:  P Kumar; J M Wang; C Bernabeu
Journal:  J Pathol       Date:  1996-04       Impact factor: 7.996

4.  CD34 expression in desmoplastic melanoma.

Authors:  M P Hoang; M A Selim; R C Bentley; J L Burchette; C R Shea
Journal:  J Cutan Pathol       Date:  2001-11       Impact factor: 1.587

5.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.

Authors:  Pernilla Wikström; Ingela Franck Lissbrant; Pär Stattin; Lars Egevad; Anders Bergh
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

6.  Expression of endoglin in human melanocytic lesions.

Authors:  G Dawn; R M MacKie
Journal:  Clin Exp Dermatol       Date:  2002-03       Impact factor: 3.470

7.  Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily.

Authors:  N P Barbara; J L Wrana; M Letarte
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

8.  Microvessel quantitation and prognosis in invasive breast carcinoma.

Authors:  S Bosari; A K Lee; R A DeLellis; B D Wiley; G J Heatley; M L Silverman
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

9.  Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer.

Authors:  Ester Fonsatti; Michele Maio
Journal:  J Transl Med       Date:  2004-06-11       Impact factor: 5.531

10.  Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).

Authors:  J P Dales; S Garcia; S Carpentier; L Andrac; O Ramuz; M N Lavaut; C Allasia; P Bonnier; C Taranger-Charpin
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more
  3 in total

1.  Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Authors:  Yolanda Piña; Colleen M Cebulla; Timothy G Murray; Armando Alegret; Sander R Dubovy; Hinda Boutrid; William Feuer; Lejla Mutapcic; Maria-Elena Jockovich
Journal:  Ophthalmic Res       Date:  2009-03-26       Impact factor: 2.892

2.  Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Tulay Koru-Sengul; Christina Decatur; William K Scott; Lubov Nathanson; Jennifer Clarke; Theodore J Lampidis
Journal:  Clin Ophthalmol       Date:  2012-05-29

3.  Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects.

Authors:  Tanja Dolinsek; Gregor Sersa; Lara Prosen; Masa Bosnjak; Monika Stimac; Urska Razborsek; Maja Cemazar
Journal:  Cancers (Basel)       Date:  2015-12-24       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.